Publications by authors named "Masahisa Yabuki"
Purpose: We evaluated the safety of gadopentetate dimeglumine (Gd-DTPA), the first contrast agent for magnetic resonance imaging, using pharmacovigilance data for spontaneously reported adverse events (AEs) after 120 million cumulative administrations worldwide.
Methods: We analyzed spontaneously reported AEs for Gd-DTPA for pre-specified time periods between 1988 and 2011.
Results: Since the market introduction of Gd-DTPA in 1988, its global utilization reached 120 million cumulative administrations in 2011, more than 80% of which was by the USA, countries in the European Union (EU), and Japan.